Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations | Synapse
September 16, 2024
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
Key Points
Key points are not available for this paper at this time.